2010 Annual Meeting
Presentations from ASENT's 12th Annual Meeting :
- Challenges in Conducting Drug Trials
- Post Marketing Trials
- Drug Development Challenges
- Pipeline Presentations
- Spectrum of Mitochondrial Dysfunction
- Comparative Effectiveness
To view a session, click 
to view
a PowerPoint slide presentation, 
to hear the audio,
and 
to view a video.
Thursday, March 4, 2010
Challenges in Conducting Drug Trials
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Clinical Trial Methods: Reducing the Challenges in Conducting Clinical Trials |
Dave Zuckerman |
19 min |
|
|
|
| IRB, Contract & Recruitment Issues |
Jacqueline A French MD for Joyce Cramer |
22 min. 33 sec. |
|
|
|
| Trial Design Complexity and its Impact on Study Conduct Performance |
Ken Getz, Tufts CSDD |
19 min. 0 sec. |
|
|
|
Challenges in Conducting International Trials
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Challenges in Conducting International Trials Trial Methods and Designs Differences from US based Trials |
Virinder Nohria, MD, PhD |
17 min. 38 sec. |
|
|
|
| Challenges in Conducting International Trials - Trans-Regional Regulatory Issues |
Gene Wright, PharmD, PhD |
20 min. 58 sec. |
|
|
|
Post Marketing Trials
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Changing Postmarket Landscape for Medical Devices |
Danica Marinac-Dabic, MD, PhD |
25 min. 28 sec. |
|
|
|
| Industry Perspective and Response |
Nancy Santilli, BSN, MSN |
21 min. 04 sec. |
|
|
|
Challenges in Conducting Device Trials
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Neurotherapeutic Devices: How Do Drugs and Devices Differ? |
Martha Morrell MD for Nina Graves PharmD |
30 min. 09 sec. |
|
|
|
Special Issues Conducting Drug Trials: Suicide Risk Associated with Neurological Therapies - Point/Counterpoint
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Special Issues in Conducting Drug Trials: Suicide Risk Associated with Neurological Therapies There is a Significant Risk |
Russell Katz, M.D. |
|
|
|
|
| The Risk Is Overstated |
Dale C. Hesdorffer, Ph.D. |
|
|
|
|
Conducting Trials in Vulnerable Populations
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Ethical consideration in Conducting trials in Vulnerable Populations |
Barbara Illowsky Karp, MD |
|
|
|
|
| Challenges in Conducting Device Trials - What Does the Future Hold for Device Trials? |
Panel Discussion |
|
|
|
|
| Pregnancy Registries |
John Messenheimer, MD |
|
|
|
|
Dinner Session: Drug Development: Overcoming Challenges in the Road Ahead
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| What Does it Really Cost to Develop a New Treatment? |
Kenneth I Kaitin, Ph.D. |
12 min. 01 sec. |
|
|
|
| Alleviating Burdens in Drug Development:The Clinical Trials Transformation Initiative (CTTI) |
Alberto Grignolo, Ph.D |
14 min. 16 sec. |
|
|
|
| Innovative Strategies for Drug Development in Small Target Populations |
Frank L. Douglas Ph.D., M.D. |
13 min. 59 sec. |
|
|
|
Friday, March 5, 2010
A: Drug Development: Challenges, Consortia and CROs
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Review of New Drug Development - Challenges for the Research-Based Industry |
Kenneth I Kaitin, Ph.D. |
43 min. 49 sec. |
|
|
|
| Contract Research Organizations: How to Select, Problems and Experiences |
Christopher C. Gallen, M.D., Ph.D. |
41 min. 45 sec. |
|
|
|
| The Duke Clinical Research Institute: An Academic Research Organization (ARO) |
John S. March, MD, MPH, |
45 min. 55 sec. |
|
|
|
| Academic Consortia: Clinical Trial Networks |
Karl Kieburtz, MD, MPH |
27 min. 22 sec. |
|
|
|
| Consortia: An Industry Perspective |
R. Michael Poole MD FACP |
24 min. 54 sec. |
|
|
|
Pipeline Projects - NIH/NINDS Support for Drug Development
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Therapeutic Development Resources at NINDS: Office of Translational Research |
William Matthew, PhD |
|
|
|
|
| A New Program to Support Drug Development: The Blueprint for Neuroscience Grand Challenge for Neurotherapeutics |
Rebecca Farkas, PhD |
|
|
|
|
Pipeline Projects - Multiple Sclerosis/Motor Neuron Disease
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis |
Stephen Glenski, PharmD |
|
|
|
|
| Novel Compounds for the Treatment of Spinal Muscular Atrophy |
Jill Heemskerk, PhD |
|
|
|
|
Pipeline Projects - Alzheimer's Disease, Neuroprotection and Cognition
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| CREB & The Development of Novel Memory Enhancers |
'Tim Tully, PhD |
|
|
|
|
| Clinical development of davunetide in AD and cognitive impairment |
Alistair Stewart, PhD |
|
|
|
|
| AAV2-NRTN (CERE-120) In Parkinson's Disease: Phase 2 Trial Results And Path Forward |
Joao Siffert, MD |
|
|
|
|
Pipeline Project - Partnerning with Large Pharma
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Merck Research Laboratories |
Susan P. Rohrer, PhD |
|
|
|
|
Pipeline Projects - Pain and Migraine
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| LEVADEX™, a Novel Orally Inhaled Treatment for Acute Migraine: Efficacy and Tolerability Results of a Phase 3 Study |
Shashidhar H Kori, MD |
|
|
|
|
| Sodium Oxybate in the Treatment of Fibromyalgia: Results from an International Phase 3 Clinical Trial |
Norman Rosenthal, MD |
|
|
|
|
| Overview of the Clinical Development EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use. |
Paul D. Meisner, PharmD |
|
|
|
|
Pipeline Projects - Movement Disorders and Neuromuscular
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Acetyl Hexapeptide-8 for Treatment of Blepharospasm |
Codrin Lungu, MD |
|
|
|
|
| Biomarker Development for HDAC Inhibitor Treatment of Friedreich’s Ataxia |
James Rusche, PhD |
|
|
|
|
| IMMUNOMODULATORY THERAPY FOR PARKINSON’S DISEASE - Induction of an anti-inflammatory immune response toward toxic species of alpha-synuclein |
Eric Zanelli, PhD |
|
|
|
|
| Human Pharmacokinetics of NBI-98854: A Selective Inhibitor of VMAT2 with an Attractive PK and Safety Profile for Hyperkinetic Movement Disorders |
Ajay Madan, PhD |
|
|
|
|
| Mitigating Effects of Oxidation in Aging and Diseases |
M. Shchepinov, R.J. Molinari *, V. Shmanai, C. Clarke, A. Manning-Bog |
|
|
|
|
Pipeline Projects - Epilepsy
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Intrapulmonary Propofol Analogs |
Michael A. Rogawski, M.D., Ph.D. |
|
|
|
|
| The NeuroPace RNS® System: Results of a Multicenter Double-Blinded Randomized Controlled Pivotal Investigation for Treatment of Intractable Partial Epilepsy |
Martha J Morrell MD |
|
|
|
|
| Novel Series of Antiseizures Compounds |
Roger Porter, MD for Stephen Collins, MD |
|
|
|
|
| An Overview of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial-Onset Seizures |
Mark Versavel MD, PhD, MBA |
|
|
|
|
| Oxcarbazepine Extended Release - OXC XR |
Janet K. Johnson, Ph.D. |
|
|
|
|
| 2DG - a glucose analogue and glycolytic inhibitor with anticonvulsant and antiepileptic actions |
Tom Sutula, MD, PhD |
|
|
|
|
Saturday, March 6, 2010
Symposium: Comparative Effectiveness
| Title |
Speaker(s) |
Duration |
Presentation |
Audio |
Video |
| Comparative effectiveness: What is it? |
Jacqueline A French MD |
19 min. 09 sec. |
|
|
|
| ACTIVE CONTROL EQUIVALENCE TRIALS: GETTING IT RIGHT |
Susan S. Ellenberg, Ph.D. |
35 min. 19 secs. |
|
|
|
| Regulatory Aspects of Comparative Trials |
Russell Katz, M.D. |
45 min. 55 sec. |
|
|
|
| Guidelines and Comparative Effectiveness trials - A different Perspective |
Gary S Gronseth, MD, FAAN |
42 min. 26 sec. |
|
|
|
| Health Economic Implications of Comparative Effectiveness: Will it Affect Who Will Pay for What and What Will be Available? |
Walter Koroshetz, MD |
48 min. 49 sec. |
|
|
|
